A compound having one of the following structures of Formula (IV) or (V):

##STR00001##

or a stereoisomer, salt, or tautomer thereof, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 R.sub.6, R.sub.7, R.sub.8, R.sub.10, R.sub.11a R.sub.11b, R.sub.12a R.sub.12b, X, Y, and Z are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

A compound having one of the following structures of Formula (IV) or (V):

##STR00001##

or a stereoisomer, salt, or tautomer thereof, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 R.sub.6, R.sub.7, R.sub.8, R.sub.10, R.sub.11a R.sub.11b, R.sub.12a R.sub.12b, X, Y, and Z are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided. ##STR00001##

The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided. ##STR00001##

The disclosure relates to novel compounds and methods of use of the compounds to maintain the Gα.sub.i2 protein in its inactive GDP-bound state. The disclosure describes the knockdown or inhibition of Gα.sub.i2 negatively regulated migration of breast and ovarian cancer cell lines. The novel compounds inhibit the migratory behavior of PC3, DU145 and E006AA prostate cancer cell lines. Specifically, the novel compounds block the activation of Gα.sub.i2 in oxytocin-stimulated prostate cancer PC3 cells and inhibits the migratory capability of DU145 cells overexpressing constitutively active form of Gα.sub.i2, under basal and EGF-stimulated conditions.

The disclosure relates to novel compounds and methods of use of the compounds to maintain the Gα.sub.i2 protein in its inactive GDP-bound state. The disclosure describes the knockdown or inhibition of Gα.sub.i2 negatively regulated migration of breast and ovarian cancer cell lines. The novel compounds inhibit the migratory behavior of PC3, DU145 and E006AA prostate cancer cell lines. Specifically, the novel compounds block the activation of Gα.sub.i2 in oxytocin-stimulated prostate cancer PC3 cells and inhibits the migratory capability of DU145 cells overexpressing constitutively active form of Gα.sub.i2, under basal and EGF-stimulated conditions.

Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

The present disclosure describes a method to treat conditions, including bacterial infections and cancer, using a photosensitive compound that, upon exposure to white light, can be activated. The photosensitive compound can also interact synergistically with antibiotics used concomitantly to kill drug-resistant bacteria. The photosensitive compounds can also be used to inhibit the proliferation of cancer cells.

The present disclosure describes a method to treat conditions, including bacterial infections and cancer, using a photosensitive compound that, upon exposure to white light, can be activated. The photosensitive compound can also interact synergistically with antibiotics used concomitantly to kill drug-resistant bacteria. The photosensitive compounds can also be used to inhibit the proliferation of cancer cells.